Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17485966 | 0.94 | ALOX5 (0.36) | ALOX5PARP14L3MBTL1BACE1BACE2 | |
| SCHEMBL17486197 | 0.88 | ALOX5 (0.36) | ALOX5PARP14L3MBTL1BACE1BACE2 | |
| SCHEMBL17486234 | 0.84 | S1PR1 (0.37) | L3MBTL1MAPTHSD17B1HSD17B2 | |
| SCHEMBL18015295 | 0.79 | HSD17B1 (0.40) | BACE1HSD17B1HSD17B2 | |
| SCHEMBL17486227 | 0.78 | HSD17B1 (0.41) | L3MBTL1MAPTHSD17B1HSD17B2 | |
| SCHEMBL17486324 | 0.77 | NR1H4 (0.37) | L3MBTL1MAPTHSD17B1HSD17B2 | |
| SCHEMBL25789532 | 0.77 | RARB (0.44) | ALOX5PARP14MAPT | |
| SCHEMBL17486244 | 0.77 | HSD17B1 (0.40) | L3MBTL1MAPTHSD17B1HSD17B2 | |
| SCHEMBL19794506 | 0.76 | RARB (0.34) | MAPTHSD17B1HSD17B2 | |
| SCHEMBL17486259 | 0.76 | HSD17B1 (0.43) | MAPTHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | ALOX5 3618/4885PARP14 1246/4885L3MBTL1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.